PortViewPortView
Epizyme logo

Epizyme (EPZM) Stock Analysis

NASDAQHealthcareBiotechnology

$1.47+0.00%
1-year price historyRange $0.42 – $5.73
52-week range$1.47
$0.41$5.80

What Epizyme does

Epizyme, Inc. is a biopharmaceutical enterprise that operates at a commercial level, dedicated to discovering, advancing, and bringing to market innovative epigenetic therapies for individuals battling cancer and other medical conditions across the United States. Its flagship commercial product is Tazemetostat, prescribed for the management of metastatic or locally advanced epithelioid sarcoma in both adult and pediatric populations. Beyond this, Epizyme is actively engaged in developing several other therapeutic candidates. These include R-CHOP for initial treatment in patients suffering from high-risk diffuse large B-cell lymphoma, and a PARP inhibitor targeting solid tumors that have become resistant to other PARP inhibitors, encompassing conditions like castration-resistant prostate cancer and small cell lung cancer. Furthermore, the company is exploring additional applications for Tazemetostat in treating INI1-negative tumors in both children and adults. Its pipeline also features a PRMT5 inhibitor intended for solid tumors and a PRMT1 inhibitor. Epizyme maintains strategic alliances and collaborative agreements with various partners, such as Roche Molecular Systems, Inc., the Lymphoma Academic Research Organization, Eisai Co. Ltd., HUTCHMED (China) Limited, and Roche Sequencing Solutions, Inc. Founded in 2007, the company's corporate headquarters are situated in Cambridge, Massachusetts. Since August 11, 2022, Epizyme, Inc. has operated as a wholly-owned subsidiary of Ipsen Biopharmaceuticals, Inc.

Key metrics

Market cap
$0
P/E (TTM)
-0.70
EPS (TTM)
$-2.09
Beta
-0.42
Dividend yield
0.00%
Revenue / share
$0.37
50-day avg
$1.25
200-day avg
$1.67
52-week high
$5.80
52-week low
$0.41
CEO
Robert Bazemore

ETFs linked to EPZM

Broad-market and Healthcare sector ETFs an investor holding Epizyme is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EPZM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze EPZM in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Epizyme?
Epizyme trades under the ticker EPZM on NASDAQ.
Which exchange is EPZM listed on?
EPZM is listed on NASDAQ.
What sector does Epizyme operate in?
Epizyme is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze EPZM in a portfolio?
PortView shows EPZM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.